- This article examines whether Herbalife, trading at around US$19.52, might be a bargain or a value trap by exploring what the current price could be implying about the company.
- The stock has had a mixed run, with a 7 day return of a 2.2% decline, a 30 day return of 18.4%, year to date gains of 52.3%, and a 1 year return of 135.2%. Over longer periods, the 3 year and 5 year returns stand at a 5.3% decline and a 58.9% decline respectively.
- Recent coverage of Herbalife has focused on its position in the household products space and how sentiment has shifted alongside that strong 1 year return. This has raised questions about whether the share price now reflects a fuller view of risks and opportunities. At the same time, longer term return figures still draw attention from investors who are weighing shorter term momentum against a more mixed multi year record.
- Under our framework, Herbalife currently scores a 5/6 valuation check. This sets up a closer look at how different models view the stock today and points to a more rounded way of thinking about value that we will return to at the end of this article.
Approach 1: Herbalife Discounted Cash Flow (DCF) Analysis
A Discounted Cash Flow, or DCF, model projects a company’s future cash flows and then discounts them back to today’s value to estimate what the business might be worth now.
For Herbalife, the model used is a 2 Stage Free Cash Flow to Equity approach based on cash flow projections. The latest twelve month free cash flow is around $220.7 million, with Simply Wall St extrapolating future free cash flows, including an estimate of $162 million for 2024 and a series of forecasts through to 2035. By projecting these values out 10 years and discounting each of them back to today using an assumed required return, the model arrives at an estimated intrinsic value per share of about $31.32.
Against a recent share price of roughly $19.52, this DCF output implies the stock trades at a 37.7% discount to that intrinsic value, which points to Herbalife looking undervalued on this cash flow based approach.
Result: UNDERVALUED
Our Discounted Cash Flow (DCF) analysis suggests Herbalife is undervalued by 37.7%. Track this in your watchlist or portfolio, or discover 46 more high quality undervalued stocks.
Approach 2: Herbalife Price vs Earnings
For a company that is generating profits, the P/E ratio is a straightforward way to think about what you are paying for each dollar of earnings. In general, higher growth expectations or lower perceived risk can support a higher “normal” P/E, while lower growth or higher risk usually points to a lower one.
Herbalife currently trades on a P/E of 8.84x. That sits below both the Personal Products industry average P/E of 22.10x and the broader peer group average of 51.43x. Simply Wall St also calculates a proprietary “Fair Ratio” for Herbalife of 16.73x, which is an estimate of the P/E you might expect given factors such as its earnings profile, industry, profit margins, market cap and company specific risks.
This Fair Ratio is more tailored than a simple comparison with peers or the industry because it adjusts for the company’s own characteristics rather than assuming all businesses should trade on the same multiple. Set against the actual P/E of 8.84x, Herbalife’s Fair Ratio of 16.73x suggests the shares are trading below that modelled range.
Result: UNDERVALUED
P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.
Upgrade Your Decision Making: Choose your Herbalife Narrative
Earlier we mentioned that there is an even better way to understand valuation. On Simply Wall St's Community page you can use Narratives, which let you set out your own story for Herbalife by linking your assumptions for future revenue, earnings, margins and fair value to the current price. These update automatically when new news or earnings arrive. You can see, for example, one Herbalife Narrative that connects a higher fair value of US$25 to a turnaround thesis, while another anchors on a lower fair value of US$8 with more cautious assumptions. This can help you decide how the current price around US$19.52 lines up with the story you believe.
For Herbalife however, we will make it really easy for you with previews of two leading Herbalife Narratives:
Fair value in this bullish narrative: US$25.00
Implied discount to that fair value at US$19.52: about 21.9%
Revenue growth used in this narrative: 4.45%
- The bullish author sees data driven distributor tools and digital platforms helping to refresh Herbalife’s global salesforce, with the aim of supporting volume and margin recovery over time.
- They factor in demand for preventative health and personalized nutrition, along with e commerce and subscription models, as supports for recurring revenue and earnings power.
- At the same time, they highlight risks around regulation, legal exposure, distributor fatigue and competition, and encourage you to test the analyst assumptions against your own view of what is realistic.
Fair value in this more cautious narrative: US$14.00
Implied premium to that fair value at US$19.52: about 39.4%
Revenue growth used in this narrative: 2.62%
- The cautious author focuses on regulatory scrutiny of multi level marketing, changing consumer preferences and flat volumes in some regions as constraints on revenue growth and margins.
- They still acknowledge efforts in technology, product development and distributor engagement, but see these as working against headwinds rather than fully reshaping the risk profile.
- In this view, analyst assumptions point to a fair value close to US$14, with the current price sitting ahead of that and leaving less room if execution or sector conditions disappoint.
Putting these side by side gives you a clear range of outcomes, from a valuation anchored around US$14 to one closer to US$25. Your own stance on Herbalife comes down to which set of assumptions you find more convincing, and whether the current price around US$19.52 feels closer to your version of fair value or not.
Do you think there's more to the story for Herbalife? Head over to our Community to see what others are saying!
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com